CLS’s acting CEO Dan J. Mogren will go on a planned sick leave

Clinical Laserthermia Systems AB (publ) (CLS), which develops advanced innovative products for high-precision image guided laser ablation, announces that its acting CEO Dan J. Mogren will go on a planned sick leave on Feb 10th until the March 31st. The Board of Directors has appointed Lars-Erik Eriksson, the company CFO and previous CEO, deputy CEO during this period.

“I will undergo a routine heart valve replacement procedure that requires open surgery and therefore demands some weeks of healing for full recovery. I hoped for the possibility of a minimally invasive procedure but unfortunately it was not possible in my case. I anticipate returning on time and look forward to a fast recovery and to come back in full power”, says Dan J. Mogren, acting CEO of CLS.

This disclosure contains information that CLS is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person set out below, on February 10th, 2022 at 08:30 CET. 

Contact information:


Lars-Erik Eriksson, CFO and Deputy CEO, Clinical Laserthermia Systems AB (publ)


Tel: +46 – (0)702 – 90 33 00
E-mail: lars-erik.eriksson@clinicallaser.com

About CLS and TRANBERG system:

Clinical Laserthermia Systems AB (publ) develops and sells the TRANBERG®|Thermal Therapy Systems, including Thermoguide Workstation and sterile disposables, for minimally invasive treatment of cancer tumors and drug-resistant epilepsy, according to regulatory approvals in the EU and the US. All components of the TRANBERG®|Thermal Therapy Systems have received EU-wide regulatory approval as medical devices (CE-marked class II) for the treatment of soft tissue lesions. CLS is developing its systems to get CE-mark class III for disposable TRANBERG laser applicators to be used in brain as well as expanding the current CE-mark for treatment with imILT®, the Company's interstitial laser thermotherapy for immunostimulatory ablation with potential abscopal effect. CLS is headquartered in Lund and has subsidiaries in Germany, the US and Singapore. CLS is listed on the Nasdaq First North Growth Market under the symbol CLS B. The Certified Advisor (CA) is FNCA Sweden AB, Tel: +46 8 528 00 399. E-mail: info@fnca.se. 

For more information about CLS, please visit the Company's website: www.clinicallaser.se

This disclosure contains information that CLS is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 10-02-2022 08:30 CET.